“Currently, the development of prophylactic drugs against COVID-19 based on several technological platforms is underway all over the world: subunit, vector replicating and vector non-replicating, RNA and DNA vaccines, inactivated, live attenuated (attenuated) and virus-like particle vaccines,” - leads RIA Novosti message.

According to Rospotrebnadzor, registration of the vaccine against coronavirus infection "EpiVacCorona" from the "Vector" center is planned to be completed by October 15.

Earlier, the WHO said that about 200 vaccines against coronavirus in the world are at the stage of clinical and preclinical trials.